Search results
Showing 541 to 555 of 983 results for death
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
the majority of people, a minority of these incidents have caused harm or death. The systematic review undertaken for this guideline...
complicated by irreversible neurological and intellectual sequelae, including death. Reasons for these complications include the...
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.